| Author | Frozza, Rudimar L. | |
| Author | Lourenco, Mychael V. | |
| Author | De Felice, Fernanda G. | |
| Access date | 2018-08-30T17:23:36Z | |
| Available date | 2018-08-30T17:23:36Z | |
| Document date | 2018 | |
| Citation | FROZZA, Rudimar L.; LOURENÇO, Mychael V.; De FELICE, Fernanda G. Challenges for Alzheimer’s Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, v.12, Article 37, 13p, Feb. 2018. | pt_BR |
| ISSN | 1662-4548, | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/28479 | |
| Language | eng | pt_BR |
| Publisher | Frontiers Media | pt_BR |
| Rights | open access | |
| Subject in Portuguese | Doença de Alzheimer | pt_BR |
| Subject in Portuguese | Inflamação | pt_BR |
| Subject in Portuguese | Terapia | pt_BR |
| Subject in Portuguese | defeitos de memória | pt_BR |
| Subject in Portuguese | pré-clínico | pt_BR |
| Subject in Portuguese | desequilíbrios metabólicos | pt_BR |
| Title | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects | pt_BR |
| Type | Article | |
| DOI | 10.3389/fnins.2018.00037 | |
| Abstract | Alzheimer's disease (AD), the most common form of dementia in late life, will become even more prevalent by midcentury, constituting a major global health concern with huge implications for individuals and society. Despite scientific breakthroughs during the past decades that have expanded our knowledge on the cellular and molecular bases of AD, therapies that effectively halt disease progression are still lacking, and focused efforts are needed to address this public health challenge. Because AD is classically recognized as a disease of memory, studies have mainly focused on investigating memory-associated brain defects. However, compelling evidence has indicated that additional brain regions, not classically linked to memory, are also affected in the course of disease. In this review, we outline the current understanding of key pathophysiological mechanisms in AD and their clinical manifestation. We also highlight how considering the complex nature of AD pathogenesis, and exploring repurposed drug approaches can pave the road toward the development of novel therapeutics for AD. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil. | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Bioquímica Médica Leopoldo de Meis. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Biofísica Carlos Chagas Filho. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Instituto de Bioquímica Médica Leopoldo de Meis. Rio de Janeiro, RJ, Brasil / Queen’s University,. Centre for Neuroscience Studies. Department of Biomedical and Molecular Sciences. Kingston, Ontario, Canada. | pt_BR |
| Subject | Alzheimer’s disease | pt_BR |
| Subject | Inflammation | pt_BR |
| Subject | metabolic derangements | pt_BR |
| Subject | memory defects | pt_BR |
| Subject | preclinical | pt_BR |
| Subject | therapy | pt_BR |
| e-ISSN | 1662-453X | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
